Groundbreaking long-acting monoclonal antibody, a collaborative effort between AstraZeneca (AZ) and Sanofi
On July 17, the U.S. Food and Drug Administration granted approval for nirsevimab, marketed under the name Beyfortus, as a groundbreaking (monoclonal antibody) preventive measure against Respiratory Syncytial Virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during…
